Yun Zhao

Dr. Yun Zhao


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2018 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
XZXichen Zheng
Xichen Zheng
ZFZhaoxu Fang
Zhaoxu Fang
XLXiaomei Liu
Xiaomei Liu
SDShengming Deng
Shengming Deng
PZPei Zhou
Pei Zhou
YHYuhui Huang
Yuhui Huang
Immune checkpoint blockade (ICB) has demonstrated curative potential in several types of cancer, but only for a small number of patients. Thus, the identification of reliable and noninvasive biomarkers for predicting ICB responsiveness is an urgent unmet need. Here, we show that ICB increased tumor vessel perfusion in treatment-sensitive EO771 and MMTV-PyVT breast tumor as well as CT26 and MCA38 colon tumor models, but not in treatment-resistant MCaP0008 and 4T1 breast tumor models. In the sensitive tumor models, the ability of anti–cytotoxic T lymphocyte–associated protein 4 or anti–programmed cell death 1 therapy to increase vessel perfusion strongly correlated with its antitumor efficacy. Moreover, globally enhanced tumor vessel perfusion could be detected by Doppler ultrasonography before changes in tumor size, which predicted final therapeutic efficacy with more than 90% sensitivity and specificity. Mechanistically, CD8+ T cell depletion, IFN-γ neutralization, or implantation of tumors in IFN-γ receptor knockout mice abrogated the vessel perfusion enhancement and antitumor effects of ICB. These results demonstrated that ICB increased vessel perfusion by promoting CD8+ T cell accumulation and IFN-γ production, indicating that increased vessel perfusion reflects the successful activation of antitumor T cell immunity by ICB. Our findings suggest that vessel perfusion can be used as a novel noninvasive indicator for predicting ICB responsiveness.

27 November 2013 in Macromolecular Bioscience
Verified
Journal Article
Closed access
PDF file
JLJiawei Lu
Jiawei Lu
WZWeidong Zhang
Weidong Zhang
LYLin Yuan
Lin Yuan
WMWenjuan Ma
Wenjuan Ma
XLXiao Li
Xiao Li
GCGaojian Chen
Gaojian Chen

11 February 2014 in Macromolecular Rapid Communications
Verified
Journal Article
Closed access
PDF file
WLWei Lu
Wei Lu
WMWenjuan Ma
Wenjuan Ma
JLJiawei Lu
Jiawei Lu
XLXiao Li
Xiao Li
YZYun Zhao
Yun Zhao
GCGaojian Chen
Gaojian Chen

21 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HZHaixia Zhou
Haixia Zhou
YGYue Ge
Yue Ge
LSLili Sun
Lili Sun
WMWenjuan Ma
Wenjuan Ma
JWJie Wu
Jie Wu
YZYun Zhao
Yun Zhao
Although the generation of BCR-ABL is the molecular hallmark of chronic myeloid leukemia (CML), the comprehensive molecular mechanisms of the disease remain unclear yet. Growth arrest specific 2 (GAS2) regulates multiple cellular functions including cell cycle, apoptosis and calpain activities. In the present study, we found GAS2 was up-regulated in CML cells including CD34+ progenitor cells compared to their normal counterparts. We utilized RNAi and the expression of dominant negative form of GAS2 (GAS2DN) to target GAS2, which resulted in calpain activity enhancement and growth inhibition of both K562 and MEG-01 cells. Targeting GAS2 also sensitized K562 cells to Imatinib mesylate (IM). GAS2DN suppressed the tumorigenic ability of MEG-01 cells and impaired the tumour growth as well. Moreover, the CD34+ cells from CML patients and healthy donors were transduced with control and GAS2DN lentiviral vectors, and the CD34+ transduced (YFP+) progeny cells (CD34+YFP+) were plated for colony-forming cell (CFC) assay. The results showed that GAS2DN inhibited the CFC production of CML cells by 57±3% (n = 3), while affected those of normal hematopoietic cells by 31±1% (n = 2). Next, we found the inhibition of CML cells by GAS2DN was dependent on calpain activity but not the degradation of beta-catenin. Lastly, we generated microarray data to identify the differentially expressed genes upon GAS2DN and validated that the expression of HNRPDL, PTK7 and UCHL5 was suppressed by GAS2DN. These 3 genes were up-regulated in CML cells compared to normal control cells and the growth of K562 cells was inhibited upon HNRPDL silence. Taken together, we have demonstrated that GAS2 is up-regulated in CML cells and the inhibition of GAS2 impairs the growth of CML cells, which indicates GAS2 is a novel regulator of CML cells and a potential therapeutic target of this disease.

5 August 2014 in Oncogene
Verified
Journal Article
Closed access
PDF file
XZX Zhang
X Zhang
WMW Ma
W Ma
JCJ Cui
J Cui
HYH Yao
H Yao
HZH Zhou
H Zhou
YZYun Zhao
Yun Zhao

16 December 2023 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
XZXiuyan Zhang
Xiuyan Zhang
WMWenjuan Ma
Wenjuan Ma
WXWen Xue
Wen Xue
YWYu Wang
Yu Wang
PCPan Chen
Pan Chen
HZHaixia Zhou
Haixia Zhou
The formation of the BCR-ABL fusion gene drives human chronic myeloid leukemia (CML). The last 2 decades have witnessed that specific tyrosine kinase inhibitors (TKIs, e.g., imatinib mesylate, IM) against ABL1 improve disease treatment, although some patients still suffer from relapse and TKI resistance. Therefore, a better understanding of the molecular pathology of CML is still urgently needed. miR-181a-5p (miR-181a) acts as a tumor suppressor in CML; however, the molecular mechanism of miR-181a in CML stem/progenitor cells remains elusive. Herein, we showed that miR-181a inhibited the growth of CML CD34+ cells, including the quiescent subset, and sensitized them to IM treatment, while miR-181a inhibition by a sponge sequence collaborated with BCR-ABL to enhance the growth of normal CD34+ cells. Transcriptome data and biochemical analysis revealed that SERPINE1 was a bona fide and critical target of miR-181a, which deepened the understanding of the regulatory mechanism of SERPINE1. Genetic and pharmacological inhibition of SERPINE1 led to apoptosis mainly mediated by caspase-9 activation. The dual inhibition of SERPINE1 and BCR-ABL exhibited a significantly stronger inhibitory effect than a single agent. Taken together, this study demonstrates that a novel miR-181a/SERPINE1 axis modulates CML stem/progenitor cells, which likely provides an important approach to override TKI resistance.